Verseau Therapeutics logo
VerifiedBiotechnology Research· Founded 2017

Verseau Therapeutics

Verseau is focused on developing the next major wave of cancer immunotherapies directed at a broad and potent reprogramming of the tumor microenvironment to attack tumors. This is accomplished by stimulating macrophages to shift their phenotype from immunosuppressive to a pro-inflammatory, anti-tumor state in a process called macrophage repolarization. Verseau developed a unique target discovery engine that leveraged patient data and computational biology to discover and validate over 20 novel macrophage targets. Verseau’s first-in-class monoclonal antibody candidates, VTX-0811 targeting PSGL-1 and VTX-1218 targeting VSIG4, are in late preclinical development and progressing toward clinical trials.

7-day free trial · no credit card

HeadquartersBedford, United StatesEmployees6(11 to 50)Annual revenue$1M to <$10MFounded year2017Websiteverseautx.comLinkedIn profileLinkedIn

Verified contacts

1

available on Kipplo

LinkedIn employees

6

11 to 50 range

Open roles

no listings

Distinct roles

1

indexed titles

Tech stack

0

tools in use

Monthly traffic

organic / mo

Sign up free to see all 1 verified contacts at Verseau Therapeutics

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Decision-makers and verified team members

1 contacts with verified email or phone · masked until revealed.

Sign up free →

No verified contacts on record for this company yet.

Top roles at Verseau Therapeutics

1 distinct titles indexed · top 1 shown.

  • 1sr research scientist

Sign up to unlock all 1 contacts at Verseau Therapeutics

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Sign up to reveal 1 verified contacts at Verseau Therapeutics

7-day trial · no credit card · cancel anytime · only pay for verified records.

Trusted by sales, marketing, and GTM engineering teams.

Verseau Therapeutics | Kipplo Discover